<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00858780</url>
  </required_header>
  <id_info>
    <org_study_id>0881K1-4500</org_study_id>
    <secondary_id>B1801016</secondary_id>
    <nct_id>NCT00858780</nct_id>
  </id_info>
  <brief_title>Study Comparing The Effect On Disease Activity When Reducing Or Discontinuing Etanercept In Subjects With RA</brief_title>
  <acronym>DOSERA</acronym>
  <official_title>Dose Reduction or Discontinuation of Etanercept in Methotrexate-Treated Rheumatoid Arthritis Subjects Who Have Achieved a Stable Low Disease Activity-state (DOSERA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study involves Rheumatoid Arthritis patients in regular clinical setting who are already
      on etanercept treatment and are in remission or in a low disease activity (LDA) state, and is
      intended to identify parameters that can serve as guidance in clinical settings. This study
      will consider the clinical and radiographic course in subjects when etanercept treatment is
      tapered or discontinued, and analyze the subjects' experience of disease worsening and the
      predictive values of clinical parameters, serum biomarkers and imaging on the clinical and
      radiographic course in different treatment groups. The effect of re-treatment with etanercept
      at treatment failure will also be studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participant Who Were Non-Failures</measure>
    <time_frame>Week 48</time_frame>
    <description>A participant was considered as non-failure if the calculated DAS28 &lt;=3.2 at all visits or if the calculated DAS28 &gt;3.2, the increase of calculated DAS28 from randomization (Week 0): was &lt;0.6 at all visit or was &gt;=0.6 but &lt;1.2 on no more than 1 consecutive visit. Percentage of participants who were non-failures calculated based on DAS28 and disease progression as determined by investigator or participant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>Randomization (Week 0) up to date of failure, withdrawal due to disease progression or last evaluation visit (Week 48)</time_frame>
    <description>TTF (in weeks): (date of failure minus date of randomization) divided by 7. Date of failure was ordinary visit date or extra visit date in case of failure (extra visit was within 2 weeks from the date a participant experienced significant disease progression between visits and wanted to withdraw from Period 2), or date of withdrawal due to disease progression. Participants who did not have a treatment failure were censored at their last evaluation visit. Participants who withdrew from the study prematurely and did not have a treatment failure were censored on the date of their withdrawal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Remission or Low Disease Activity (LDA)</measure>
    <time_frame>Baseline (Week -8), Week -4, Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>Participants who had DAS28 less than or equal to (&lt;=) 3.2 were considered in remission or LDA state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Visits During Which Participants Were in Remission or Low Disease Activity State</measure>
    <time_frame>Randomization (Week 0) up to Week 48</time_frame>
    <description>Participants who had DAS28 &lt;=3.2 were considered in remission or LDA state. Percentage of visits during which a participant was in remission or LDA state was calculated as number of visits in which participant was in remission or LDA divided by total number of visits multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Based on 28-Joint Count (DAS28) at Randomization</measure>
    <time_frame>Randomization (Week 0)</time_frame>
    <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 &lt;=3.2 implied low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Disease Activity Score Based on 28-Joint Count (DAS28) at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>DAS28 calculated from SJC and PJC using the 28 joints count, the ESR (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 &lt;=3.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity and &lt;2.6=remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Tender Joints Count (TJC) at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from randomization indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Swollen Joints Count (SJC) at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from randomization indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Physician Global Assessment (PGA) of Disease Activity at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>PGA of disease activity was measured on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), with 0 mm = no disease activity and 100 mm = extreme disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Participant Global Assessment (PtGA) of Disease Activity at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>Participants assessed the overall activity of their rheumatoid arthritis (RA) on a 0 to 100 mm VAS, where 0 mm = no disease activity and 100 mm = extreme disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant General Health Visual Analog Scale (VAS) at Randomization</measure>
    <time_frame>Randomization (Week 0)</time_frame>
    <description>Participants answered &quot;in general how would you rate your health over the last 2-3 weeks?&quot; Participants responded by using a 0 to 100 mm VAS, where 0 mm = very well and 100 mm = extremely bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Participant General Health Visual Analog Scale (VAS) at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>Participants answered &quot;in general how would you rate your health over the last 2-3 weeks?&quot; Participants responded by using a 0 to 100 mm VAS, where 0 mm = very well and 100 mm = extremely bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Pain Visual Analog Scale (VAS) at Randomization</measure>
    <time_frame>Randomization (Week 0)</time_frame>
    <description>Participants indicated the amount of pain experience during the last 2-3 days by marking a vertical line on 100 mm VAS. Intensity of pain range: 0 = no pain to 100 = pain as bad as it could be.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Participant Pain Visual Analog Scale (VAS) at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>Participants indicated the amount of pain experience during the last 2-3 days by marking a vertical line on 100 mm VAS. Intensity of pain range: 0 = no pain to 100 = pain as bad as it could be.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Morning Stiffness Duration at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. The duration of morning stiffness was determined by asking the following questions: 1) Over the last 2 days, when did you wake in the morning? 2) Over the last 2 days, when were you able to resume your normal activities without stiffness? Increase in stiffness duration from randomization represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Erythrocyte Sedimentation Rate (ESR) at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter per hour (mm/hour). A higher rate is consistent with inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in C-Reactive Protein (CRP) Level at Week 6, 12, 18, 24, 30, 36, 42, and 48</measure>
    <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;10 milligram per liter (mg/L). A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Modified Total Sharp Score (mTSS) at Week 48</measure>
    <time_frame>Randomization (Week 0), Week 48</time_frame>
    <description>mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at randomization. An increase in mTSS from randomization represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Magnetic Resonance Imaging (MRI) Findings at Randomization</measure>
    <time_frame>Randomization (Week 0)</time_frame>
    <description>MRI of hand/wrist of dominant hand scored for signs of synovitis (S-score), bone edema(O-score), bone erosions (E-score) as per outcome measures in RA clinical trials (OMERACT). S-score:0(normal)-3(severe) for distal radioulnar,radiocarpal,intercarpal-carpometacarpal,second-fifth metacarpophalangeal joints, total score(TS)0-21, higher score(HS)=severe synovitis. O-score:0(no volume increment)-3(100% volume increment) in 23 hand/wrist joints, TS 0-69, HS=more edema. E-score:0(no volume occupied by erosion)-10(100% volume occupied by erosion) in 23 hand/wrist joints, TS 0-230, HS=more erosion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Magnetic Resonance Imaging (MRI) Findings (S-Score) at Week 12</measure>
    <time_frame>Randomization (Week 0), Week 12</time_frame>
    <description>MRI of hand/wrist of dominant hand was scored for signs of synovitis (S-score), bone edema (O-score), and bone erosions (E-score) as per OMERACT. S-score: 0 (normal) to 3 (severe) for each of distal radioulnar, radiocarpal, intercarpal-carpometacarpal, second to fifth metacarpophalangeal joints; total score 0 to 21, higher score=severe synovitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Randomization in Magnetic Resonance Imaging (MRI) Findings (O-Score, E-Score) at Week 12</measure>
    <time_frame>Randomization (Week 0), Week 12</time_frame>
    <description>MRI of hand/wrist of dominant hand was scored for signs of synovitis (S-score), bone edema (O-score), and bone erosions (E-score) as per OMERACT. O-score: 0 (no volume increment) to 3 (100% volume increment) in 23 hand/wrist joints; total score 0 to 69, higher scores=more edema. E-score: 0 (no volume occupied by erosion) to 10 (100% volume occupied by erosion) in 23 hand/wrist joints; total score 0 to 230, higher scores=more erosion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Treatment Failure for Each Potentially Predictor Variable at Randomization</measure>
    <time_frame>Randomization (Week 0) up to Week 48</time_frame>
    <description>Percentage of participants who were treatment failure over 48 weeks as per potentially predictor variables (at randomization) are reported: number of swollen joints/tender joints, DAS28, PGA, PtGA, participant general health VAS, participant pain VAS, clinical disease activity index (CDAI), simplified disease activity index (SDAI), ESR (mm/hour), plasma CRP (mg/L), sensitive serum CRP (mg/L), anti- cyclic citrullinated peptide (anti CCP, units/mL), cartilage oligomeric matrix protein (COMP, units/liter), S-score, O-score, E-score, Joint space narrowing score, erosion score, and mTSS.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50mg once weekly + methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25mg once weekly + methotrexate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>once weekly + methotrexate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>50 mg etanercept once weekly + methotrexate</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>25mg etanercept once weekly + methotrexate</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo comparator once weekly + methotrexate</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subject has a current DAS28 equal to or less than 3.2.

          -  Subject is currently receiving treatment with etanercept, either 25 mg twice weekly or
             50 mg once weekly, for a minimum of 14 months at baseline

          -  Subject is currently receiving oral, sc or intramuscular methotrexate once weekly, 7.5
             mg/week to 25 mg/week and at a stable dose for a minimum of 4 months at baseline.

        Exclusion Criteria:

          -  Subject has earlier had an attempt of discontinuing etanercept for reasons of
             remission or low disease activity state.

          -  Subject has received any disease-modifying anti-rheumatic drug, other than
             methotrexate, within one month before baseline.

          -  Subject has had a dose of prednisone (or equivalent) &gt;7.5 mg/day or has received
             intra-articular, intravenous, intramuscular, or subcutaneous corticosteroid within one
             month of baseline.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>FI-00029 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Jyvaskyla</city>
        <zip>40620</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gyula</city>
        <zip>5701</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Reykjavik</city>
        <zip>108</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lillehammer</city>
        <zip>2609</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oslo</city>
        <zip>0319</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Malmo</city>
        <zip>SE-205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Iceland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0881K1-4500&amp;StudyName=Study%20Comparing%20The%20Effect%20On%20Disease%20Activity%20When%20Reducing%20Or%20Discontinuing%20Etanercept%20In%20Subjects%20With%20RA</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2009</study_first_submitted>
  <study_first_submitted_qc>March 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2009</study_first_posted>
  <results_first_submitted>June 6, 2013</results_first_submitted>
  <results_first_submitted_qc>June 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2013</results_first_posted>
  <last_update_submitted>August 30, 2013</last_update_submitted>
  <last_update_submitted_qc>August 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Etanercept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Etanercept 50 mg – Period 1</title>
          <description>Etanercept 50 milligram (mg) subcutaneous (SC) injection once weekly along with methotrexate (MTX) 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or intramuscular (IM) injection, depending on the dose a participant was receiving at time of screening, for 8 weeks. Participants who maintained disease activity score based on 28-joints count (DAS28) less than or equal to (&lt;=) 3.2 in Period 1 were randomized in Period 2.</description>
        </group>
        <group group_id="P2">
          <title>Etanercept 50 mg – Period 2</title>
          <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
        </group>
        <group group_id="P3">
          <title>Etanercept 25 mg – Period 2</title>
          <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
        </group>
        <group group_id="P4">
          <title>Placebo – Period 2</title>
          <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
        </group>
        <group group_id="P5">
          <title>Etanercept 50 mg – Period 3</title>
          <description>Participants, who showed treatment failure in Period 2, received etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to Week 48/early termination.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Open-Label (OL) Run-In(Week-8 to Week 0)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not enter double-blind period</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-Blind (Week 0 to Failure/Week 48)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="23"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="22"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OL Re-Treatment (Failure to Week 48)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="43">43 participants showed treatment failure in Period 2 and entered in Period 3.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Includes all participants who were enrolled in this study.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.14" spread="11.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participant Who Were Non-Failures</title>
        <description>A participant was considered as non-failure if the calculated DAS28 &lt;=3.2 at all visits or if the calculated DAS28 &gt;3.2, the increase of calculated DAS28 from randomization (Week 0): was &lt;0.6 at all visit or was &gt;=0.6 but &lt;1.2 on no more than 1 consecutive visit. Percentage of participants who were non-failures calculated based on DAS28 and disease progression as determined by investigator or participant.</description>
        <time_frame>Week 48</time_frame>
        <population>Modified intent-to-treat (m-ITT) analysis set included all randomized participants who received at least 1 dose of study medication after randomization and had at least 1 available evaluation after the first administration of study medication after randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participant Who Were Non-Failures</title>
          <description>A participant was considered as non-failure if the calculated DAS28 &lt;=3.2 at all visits or if the calculated DAS28 &gt;3.2, the increase of calculated DAS28 from randomization (Week 0): was &lt;0.6 at all visit or was &gt;=0.6 but &lt;1.2 on no more than 1 consecutive visit. Percentage of participants who were non-failures calculated based on DAS28 and disease progression as determined by investigator or participant.</description>
          <population>Modified intent-to-treat (m-ITT) analysis set included all randomized participants who received at least 1 dose of study medication after randomization and had at least 1 available evaluation after the first administration of study medication after randomization.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.2"/>
                    <measurement group_id="O2" value="44.4"/>
                    <measurement group_id="O3" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using a generalized estimating equations (GEE) model, using a logit link, a binomial distribution and an auto-regressive correlation structure, with treatment groups, visits, their interaction, and the stratification factor as factors in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>GEE Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.72</ci_lower_limit>
            <ci_upper_limit>29.82</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using a GEE model, using a logit link, a binomial distribution and an auto-regressive correlation structure, with treatment groups, visits, their interaction, and the stratification factor as factors in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.362</p_value>
            <method>GEE Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>5.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using a GEE model, using a logit link, a binomial distribution and an auto-regressive correlation structure, with treatment groups, visits, their interaction, and the stratification factor as factors in the model.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.044</p_value>
            <method>GEE Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>16.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Treatment Failure (TTF)</title>
        <description>TTF (in weeks): (date of failure minus date of randomization) divided by 7. Date of failure was ordinary visit date or extra visit date in case of failure (extra visit was within 2 weeks from the date a participant experienced significant disease progression between visits and wanted to withdraw from Period 2), or date of withdrawal due to disease progression. Participants who did not have a treatment failure were censored at their last evaluation visit. Participants who withdrew from the study prematurely and did not have a treatment failure were censored on the date of their withdrawal.</description>
        <time_frame>Randomization (Week 0) up to date of failure, withdrawal due to disease progression or last evaluation visit (Week 48)</time_frame>
        <population>m-ITT analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Treatment Failure (TTF)</title>
          <description>TTF (in weeks): (date of failure minus date of randomization) divided by 7. Date of failure was ordinary visit date or extra visit date in case of failure (extra visit was within 2 weeks from the date a participant experienced significant disease progression between visits and wanted to withdraw from Period 2), or date of withdrawal due to disease progression. Participants who did not have a treatment failure were censored at their last evaluation visit. Participants who withdrew from the study prematurely and did not have a treatment failure were censored on the date of their withdrawal.</description>
          <population>m-ITT analysis set.</population>
          <units>weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0" lower_limit="18.1">Upper limit of confidence interval was not evaluable since there were only 50% treatment failures and there was lack of information on the later failure times.</measurement>
                    <measurement group_id="O2" value="36.1" lower_limit="15.6">Upper limit of confidence interval was not evaluable since there were only 50% treatment failures and there was lack of information on the later failure times.</measurement>
                    <measurement group_id="O3" value="6.1" lower_limit="4.0" upper_limit="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Remission or Low Disease Activity (LDA)</title>
        <description>Participants who had DAS28 less than or equal to (&lt;=) 3.2 were considered in remission or LDA state.</description>
        <time_frame>Baseline (Week -8), Week -4, Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time-point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Remission or Low Disease Activity (LDA)</title>
          <description>Participants who had DAS28 less than or equal to (&lt;=) 3.2 were considered in remission or LDA state.</description>
          <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time-point for each treatment arm, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n= 19, 23, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week -4 (n= 23, 26, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Randomization (n= 22, 27, 23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="96.3"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n= 21, 26, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5"/>
                    <measurement group_id="O2" value="80.8"/>
                    <measurement group_id="O3" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n= 18, 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18 (n= 16, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5"/>
                    <measurement group_id="O2" value="89.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n= 14, 16, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.9"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Visits During Which Participants Were in Remission or Low Disease Activity State</title>
        <description>Participants who had DAS28 &lt;=3.2 were considered in remission or LDA state. Percentage of visits during which a participant was in remission or LDA state was calculated as number of visits in which participant was in remission or LDA divided by total number of visits multiplied by 100.</description>
        <time_frame>Randomization (Week 0) up to Week 48</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Visits During Which Participants Were in Remission or Low Disease Activity State</title>
          <description>Participants who had DAS28 &lt;=3.2 were considered in remission or LDA state. Percentage of visits during which a participant was in remission or LDA state was calculated as number of visits in which participant was in remission or LDA divided by total number of visits multiplied by 100.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>percentage of visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="31.1"/>
                    <measurement group_id="O2" value="74.8" spread="38.0"/>
                    <measurement group_id="O3" value="55.3" spread="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Based on 28-Joint Count (DAS28) at Randomization</title>
        <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 &lt;=3.2 implied low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
        <time_frame>Randomization (Week 0)</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Based on 28-Joint Count (DAS28) at Randomization</title>
          <description>DAS28 calculated from the number of swollen joints (SJC) and painful joints (PJC) using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour [mm/hour]) and patient's global assessment (PtGA) of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 &lt;=3.2 implied low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity and less than (&lt;) 2.6=remission.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.86" spread="0.62"/>
                    <measurement group_id="O2" value="1.93" spread="0.85"/>
                    <measurement group_id="O3" value="1.93" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Disease Activity Score Based on 28-Joint Count (DAS28) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>DAS28 calculated from SJC and PJC using the 28 joints count, the ESR (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 &lt;=3.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity and &lt;2.6=remission.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Disease Activity Score Based on 28-Joint Count (DAS28) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>DAS28 calculated from SJC and PJC using the 28 joints count, the ESR (mm/hour) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 &lt;=3.2 = low disease activity, DAS28 &gt;3.2 to 5.1 = moderate to high disease activity and &lt;2.6=remission.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" spread="0.24"/>
                    <measurement group_id="O2" value="0.47" spread="0.25"/>
                    <measurement group_id="O3" value="0.85" spread="0.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" spread="0.25"/>
                    <measurement group_id="O2" value="0.32" spread="0.26"/>
                    <measurement group_id="O3" value="1.33" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.25"/>
                    <measurement group_id="O2" value="0.64" spread="0.27"/>
                    <measurement group_id="O3" value="1.14" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.26"/>
                    <measurement group_id="O2" value="0.66" spread="0.28"/>
                    <measurement group_id="O3" value="1.02" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.26"/>
                    <measurement group_id="O2" value="0.74" spread="0.28"/>
                    <measurement group_id="O3" value="1.12" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" spread="0.26"/>
                    <measurement group_id="O2" value="1.00" spread="0.28"/>
                    <measurement group_id="O3" value="0.45" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" spread="0.27"/>
                    <measurement group_id="O2" value="0.45" spread="0.29"/>
                    <measurement group_id="O3" value="1.02" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.27"/>
                    <measurement group_id="O2" value="0.92" spread="0.29"/>
                    <measurement group_id="O3" value="1.17" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Tender Joints Count (TJC) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from randomization indicates an improvement.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Tender Joints Count (TJC) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from randomization indicates an improvement.</description>
          <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>tender joints</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=23,27,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n= 22, 26, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2" upper_limit="6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2" upper_limit="9"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n= 18, 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2" upper_limit="2"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18 (n= 16, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2" upper_limit="6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 14, 16, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="7"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2" upper_limit="7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-1" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2" upper_limit="4"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O3" value="-0.5" lower_limit="-1" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Swollen Joints Count (SJC) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from randomization indicates an improvement.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Swollen Joints Count (SJC) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from randomization indicates an improvement.</description>
          <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>swollen joints</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=23,27,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0" upper_limit="3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n= 22, 26, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="11"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n= 18, 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="4"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18 (n= 16, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-3" upper_limit="8"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 14, 16, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-3" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2" upper_limit="5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-3" upper_limit="3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="0" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Physician Global Assessment (PGA) of Disease Activity at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>PGA of disease activity was measured on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), with 0 mm = no disease activity and 100 mm = extreme disease activity.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Physician Global Assessment (PGA) of Disease Activity at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>PGA of disease activity was measured on a 0 to 100 millimeter (mm) Visual Analog Scale (VAS), with 0 mm = no disease activity and 100 mm = extreme disease activity.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=23,27,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="0.0" upper_limit="13.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="0.0" upper_limit="30.5"/>
                    <measurement group_id="O3" value="2.25" lower_limit="0.0" upper_limit="19.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n= 22, 26, 14)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="-8.0" upper_limit="20.5"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-7.0" upper_limit="58.0"/>
                    <measurement group_id="O3" value="4.00" lower_limit="-9.0" upper_limit="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n= 18, 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-6.0" upper_limit="17.0"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-7.0" upper_limit="14.0"/>
                    <measurement group_id="O3" value="6.75" lower_limit="-4.5" upper_limit="42.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18 (n= 16, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="-11.0" upper_limit="18.0"/>
                    <measurement group_id="O2" value="4.00" lower_limit="-7.0" upper_limit="32.0"/>
                    <measurement group_id="O3" value="10.00" lower_limit="-4.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-9.0" upper_limit="8.0"/>
                    <measurement group_id="O2" value="2.00" lower_limit="-7.0" upper_limit="23.0"/>
                    <measurement group_id="O3" value="8.00" lower_limit="-5.0" upper_limit="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-3.0" upper_limit="55.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-7.0" upper_limit="35.0"/>
                    <measurement group_id="O3" value="5.00" lower_limit="-5.0" upper_limit="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="9.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-7.5" upper_limit="36.0"/>
                    <measurement group_id="O3" value="-6.50" lower_limit="-16.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="-6.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-9.0" upper_limit="3.0"/>
                    <measurement group_id="O3" value="-3.00" lower_limit="-6.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.25" lower_limit="-3.0" upper_limit="16.0"/>
                    <measurement group_id="O2" value="-1.75" lower_limit="-8.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="-1.50" lower_limit="-3.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Participant Global Assessment (PtGA) of Disease Activity at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>Participants assessed the overall activity of their rheumatoid arthritis (RA) on a 0 to 100 mm VAS, where 0 mm = no disease activity and 100 mm = extreme disease activity.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Participant Global Assessment (PtGA) of Disease Activity at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>Participants assessed the overall activity of their rheumatoid arthritis (RA) on a 0 to 100 mm VAS, where 0 mm = no disease activity and 100 mm = extreme disease activity.</description>
          <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=23,27,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.00" lower_limit="0.0" upper_limit="72.0"/>
                    <measurement group_id="O2" value="12.00" lower_limit="0.0" upper_limit="52.5"/>
                    <measurement group_id="O3" value="13.00" lower_limit="0.0" upper_limit="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n= 22, 26, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="-20.0" upper_limit="42.5"/>
                    <measurement group_id="O2" value="0.25" lower_limit="-25.5" upper_limit="57.0"/>
                    <measurement group_id="O3" value="10.00" lower_limit="-33.0" upper_limit="57.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n= 18, 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" lower_limit="-18.5" upper_limit="16.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-15.0" upper_limit="28.0"/>
                    <measurement group_id="O3" value="18.00" lower_limit="-28.0" upper_limit="51.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18 (n= 16, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-18.5" upper_limit="62.0"/>
                    <measurement group_id="O2" value="-0.50" lower_limit="-9.5" upper_limit="26.0"/>
                    <measurement group_id="O3" value="20.00" lower_limit="-27.0" upper_limit="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 14, 16, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-22.5" upper_limit="10.0"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-18.5" upper_limit="27.0"/>
                    <measurement group_id="O3" value="4.00" lower_limit="-22.0" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-22.5" upper_limit="47.0"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-29.5" upper_limit="9.5"/>
                    <measurement group_id="O3" value="-5.50" lower_limit="-27.0" upper_limit="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-24.5" upper_limit="13.0"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-9.5" upper_limit="16.5"/>
                    <measurement group_id="O3" value="-24.00" lower_limit="-38.0" upper_limit="-10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-21.5" upper_limit="29.0"/>
                    <measurement group_id="O2" value="-0.25" lower_limit="-28.5" upper_limit="27.0"/>
                    <measurement group_id="O3" value="-7.50" lower_limit="-27.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="-24.0" upper_limit="22.0"/>
                    <measurement group_id="O2" value="-1.00" lower_limit="-34.5" upper_limit="12.0"/>
                    <measurement group_id="O3" value="-7.00" lower_limit="-26.0" upper_limit="12.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant General Health Visual Analog Scale (VAS) at Randomization</title>
        <description>Participants answered “in general how would you rate your health over the last 2-3 weeks?” Participants responded by using a 0 to 100 mm VAS, where 0 mm = very well and 100 mm = extremely bad.</description>
        <time_frame>Randomization (Week 0)</time_frame>
        <population>m-ITT analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant General Health Visual Analog Scale (VAS) at Randomization</title>
          <description>Participants answered “in general how would you rate your health over the last 2-3 weeks?” Participants responded by using a 0 to 100 mm VAS, where 0 mm = very well and 100 mm = extremely bad.</description>
          <population>m-ITT analysis set.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.43" spread="12.87"/>
                    <measurement group_id="O2" value="15.11" spread="13.15"/>
                    <measurement group_id="O3" value="18.52" spread="15.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Participant General Health Visual Analog Scale (VAS) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>Participants answered “in general how would you rate your health over the last 2-3 weeks?” Participants responded by using a 0 to 100 mm VAS, where 0 mm = very well and 100 mm = extremely bad.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Participant General Health Visual Analog Scale (VAS) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>Participants answered “in general how would you rate your health over the last 2-3 weeks?” Participants responded by using a 0 to 100 mm VAS, where 0 mm = very well and 100 mm = extremely bad.</description>
          <population>m-ITT analysis set.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.21" spread="4.74"/>
                    <measurement group_id="O2" value="8.67" spread="4.70"/>
                    <measurement group_id="O3" value="8.37" spread="6.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.09" spread="5.03"/>
                    <measurement group_id="O2" value="10.21" spread="4.86"/>
                    <measurement group_id="O3" value="18.47" spread="10.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.14" spread="5.16"/>
                    <measurement group_id="O2" value="12.29" spread="4.93"/>
                    <measurement group_id="O3" value="11.30" spread="13.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.86" spread="5.42"/>
                    <measurement group_id="O2" value="9.70" spread="5.09"/>
                    <measurement group_id="O3" value="-0.15" spread="13.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.09" spread="5.38"/>
                    <measurement group_id="O2" value="13.84" spread="5.11"/>
                    <measurement group_id="O3" value="6.88" spread="13.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.18" spread="5.49"/>
                    <measurement group_id="O2" value="17.49" spread="5.16"/>
                    <measurement group_id="O3" value="-3.20" spread="16.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.15" spread="5.62"/>
                    <measurement group_id="O2" value="14.01" spread="5.26"/>
                    <measurement group_id="O3" value="29.87" spread="16.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.04" spread="5.63"/>
                    <measurement group_id="O2" value="16.09" spread="5.26"/>
                    <measurement group_id="O3" value="6.36" spread="16.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Pain Visual Analog Scale (VAS) at Randomization</title>
        <description>Participants indicated the amount of pain experience during the last 2-3 days by marking a vertical line on 100 mm VAS. Intensity of pain range: 0 = no pain to 100 = pain as bad as it could be.</description>
        <time_frame>Randomization (Week 0)</time_frame>
        <population>m-ITT analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant Pain Visual Analog Scale (VAS) at Randomization</title>
          <description>Participants indicated the amount of pain experience during the last 2-3 days by marking a vertical line on 100 mm VAS. Intensity of pain range: 0 = no pain to 100 = pain as bad as it could be.</description>
          <population>m-ITT analysis set.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.59" spread="18.16"/>
                    <measurement group_id="O2" value="12.96" spread="10.92"/>
                    <measurement group_id="O3" value="13.37" spread="10.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Participant Pain Visual Analog Scale (VAS) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>Participants indicated the amount of pain experience during the last 2-3 days by marking a vertical line on 100 mm VAS. Intensity of pain range: 0 = no pain to 100 = pain as bad as it could be.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Participant Pain Visual Analog Scale (VAS) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>Participants indicated the amount of pain experience during the last 2-3 days by marking a vertical line on 100 mm VAS. Intensity of pain range: 0 = no pain to 100 = pain as bad as it could be.</description>
          <population>m-ITT analysis set.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.90" spread="3.32"/>
                    <measurement group_id="O2" value="5.67" spread="3.69"/>
                    <measurement group_id="O3" value="22.70" spread="6.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="3.56"/>
                    <measurement group_id="O2" value="8.05" spread="3.84"/>
                    <measurement group_id="O3" value="34.27" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="3.61"/>
                    <measurement group_id="O2" value="12.21" spread="3.90"/>
                    <measurement group_id="O3" value="12.91" spread="12.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.18" spread="3.88"/>
                    <measurement group_id="O2" value="7.46" spread="4.06"/>
                    <measurement group_id="O3" value="11.32" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" spread="3.81"/>
                    <measurement group_id="O2" value="7.13" spread="4.08"/>
                    <measurement group_id="O3" value="15.97" spread="12.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.05" spread="3.90"/>
                    <measurement group_id="O2" value="13.00" spread="4.15"/>
                    <measurement group_id="O3" value="1.46" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="4.02"/>
                    <measurement group_id="O2" value="12.84" spread="4.26"/>
                    <measurement group_id="O3" value="7.13" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="4.06"/>
                    <measurement group_id="O2" value="9.13" spread="4.28"/>
                    <measurement group_id="O3" value="6.47" spread="14.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Morning Stiffness Duration at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. The duration of morning stiffness was determined by asking the following questions: 1) Over the last 2 days, when did you wake in the morning? 2) Over the last 2 days, when were you able to resume your normal activities without stiffness? Increase in stiffness duration from randomization represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Morning Stiffness Duration at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. The duration of morning stiffness was determined by asking the following questions: 1) Over the last 2 days, when did you wake in the morning? 2) Over the last 2 days, when were you able to resume your normal activities without stiffness? Increase in stiffness duration from randomization represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=23,26,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="0" upper_limit="240"/>
                    <measurement group_id="O2" value="0.5" lower_limit="0" upper_limit="240"/>
                    <measurement group_id="O3" value="5.0" lower_limit="0" upper_limit="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n= 22, 25, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-60" upper_limit="50"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-30" upper_limit="120"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-5" upper_limit="1440"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n= 18, 20, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-15" upper_limit="10"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-30" upper_limit="1410"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18 (n= 16, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0" upper_limit="1410"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-30" upper_limit="1410"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-5" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 14, 16, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-30" upper_limit="5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-60" upper_limit="90"/>
                    <measurement group_id="O3" value="0.0" lower_limit="-5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-15" upper_limit="330"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-110" upper_limit="60"/>
                    <measurement group_id="O3" value="-5.0" lower_limit="-15" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-15" upper_limit="0"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-120" upper_limit="60"/>
                    <measurement group_id="O3" value="-2.5" lower_limit="-5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42 (n= 12, 11, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-10" upper_limit="5"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-120" upper_limit="60"/>
                    <measurement group_id="O3" value="-2.5" lower_limit="-5" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 12, 11, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="-10" upper_limit="15"/>
                    <measurement group_id="O2" value="0.0" lower_limit="-30" upper_limit="60"/>
                    <measurement group_id="O3" value="-5.0" lower_limit="-10" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Erythrocyte Sedimentation Rate (ESR) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter per hour (mm/hour). A higher rate is consistent with inflammation.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Erythrocyte Sedimentation Rate (ESR) at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 millimeter per hour (mm/hour). A higher rate is consistent with inflammation.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>mm/hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=22,27,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.00" lower_limit="2.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="8.00" lower_limit="1.0" upper_limit="22.0"/>
                    <measurement group_id="O3" value="8.00" lower_limit="1.0" upper_limit="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n= 21, 26, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-8.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-14.0" upper_limit="26.0"/>
                    <measurement group_id="O3" value="2.00" lower_limit="-6.0" upper_limit="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n= 17, 21, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-7.0" upper_limit="15.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-8.0" upper_limit="11.0"/>
                    <measurement group_id="O3" value="0.50" lower_limit="-8.0" upper_limit="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18 (n= 15, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="-6.0" upper_limit="25.0"/>
                    <measurement group_id="O2" value="1.00" lower_limit="-7.0" upper_limit="32.0"/>
                    <measurement group_id="O3" value="2.00" lower_limit="-6.0" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 14, 16, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.00" lower_limit="-14.0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-5.0" upper_limit="21.0"/>
                    <measurement group_id="O3" value="1.00" lower_limit="-6.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" lower_limit="-15.0" upper_limit="23.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-4.0" upper_limit="27.0"/>
                    <measurement group_id="O3" value="1.00" lower_limit="-4.0" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-7.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="1.50" lower_limit="-5.0" upper_limit="45.0"/>
                    <measurement group_id="O3" value="-2.50" lower_limit="-6.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.50" lower_limit="-14.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-7.0" upper_limit="11.0"/>
                    <measurement group_id="O3" value="-0.50" lower_limit="-4.0" upper_limit="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="-4.0" upper_limit="36.0"/>
                    <measurement group_id="O2" value="1.00" lower_limit="-3.0" upper_limit="43.0"/>
                    <measurement group_id="O3" value="-2.50" lower_limit="-6.0" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in C-Reactive Protein (CRP) Level at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;10 milligram per liter (mg/L). A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Randomization (Week 0), Week 6, 12, 18, 24, 30, 36, 42, 48</time_frame>
        <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in C-Reactive Protein (CRP) Level at Week 6, 12, 18, 24, 30, 36, 42, and 48</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;10 milligram per liter (mg/L). A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>m-ITT analysis set. Here, ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=23,27,23)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="0.6" upper_limit="12.0"/>
                    <measurement group_id="O2" value="3.00" lower_limit="0.2" upper_limit="66.0"/>
                    <measurement group_id="O3" value="1.60" lower_limit="0.6" upper_limit="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n= 22, 26, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-9.0" upper_limit="59.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-33.2" upper_limit="31.7"/>
                    <measurement group_id="O3" value="0.33" lower_limit="-3.0" upper_limit="17.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12 (n= 18, 20, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-10.0" upper_limit="44.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-63.4" upper_limit="12.0"/>
                    <measurement group_id="O3" value="0.00" lower_limit="-3.0" upper_limit="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 18 (n= 16, 19, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="12.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-4.0" upper_limit="139.0"/>
                    <measurement group_id="O3" value="2.74" lower_limit="1.0" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 24 (n= 14, 16, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-3.1" upper_limit="2.5"/>
                    <measurement group_id="O3" value="1.00" lower_limit="0.2" upper_limit="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 30 (n= 14, 15, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.0" upper_limit="5.1"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-3.0" upper_limit="9.0"/>
                    <measurement group_id="O3" value="1.20" lower_limit="1.0" upper_limit="73.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 36 (n= 13, 14, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.0" upper_limit="2.9"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-5.0" upper_limit="29.8"/>
                    <measurement group_id="O3" value="0.94" lower_limit="0.0" upper_limit="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 42 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-3.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-3.1" upper_limit="1.0"/>
                    <measurement group_id="O3" value="3.49" lower_limit="3.0" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 12, 12, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-4.0" upper_limit="45.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-5.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="-1.42" lower_limit="-3.8" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Modified Total Sharp Score (mTSS) at Week 48</title>
        <description>mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at randomization. An increase in mTSS from randomization represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
        <time_frame>Randomization (Week 0), Week 48</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Modified Total Sharp Score (mTSS) at Week 48</title>
          <description>mTSS = sum of erosion and Joint Space Narrowing (JSN) scores for 44 joints (16 per hand and 6 per foot). mTSS scores ranged from 0 (normal) to 448 (worst possible total score). Change: scores at observation minus score at randomization. An increase in mTSS from randomization represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants evaluable for each time point for each treatment arm, respectively.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Randomization (n=19, 22, 17)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.50" lower_limit="0.5" upper_limit="176.0"/>
                    <measurement group_id="O2" value="54.25" lower_limit="3.5" upper_limit="219.0"/>
                    <measurement group_id="O3" value="23.00" lower_limit="4.0" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 48 (n= 9, 9, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-1.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-2.0" upper_limit="0.5"/>
                    <measurement group_id="O3" value="-1.00" lower_limit="-1.0" upper_limit="-1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Magnetic Resonance Imaging (MRI) Findings at Randomization</title>
        <description>MRI of hand/wrist of dominant hand scored for signs of synovitis (S-score), bone edema(O-score), bone erosions (E-score) as per outcome measures in RA clinical trials (OMERACT). S-score:0(normal)-3(severe) for distal radioulnar,radiocarpal,intercarpal-carpometacarpal,second-fifth metacarpophalangeal joints, total score(TS)0-21, higher score(HS)=severe synovitis. O-score:0(no volume increment)-3(100% volume increment) in 23 hand/wrist joints, TS 0-69, HS=more edema. E-score:0(no volume occupied by erosion)-10(100% volume occupied by erosion) in 23 hand/wrist joints, TS 0-230, HS=more erosion.</description>
        <time_frame>Randomization (Week 0)</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Magnetic Resonance Imaging (MRI) Findings at Randomization</title>
          <description>MRI of hand/wrist of dominant hand scored for signs of synovitis (S-score), bone edema(O-score), bone erosions (E-score) as per outcome measures in RA clinical trials (OMERACT). S-score:0(normal)-3(severe) for distal radioulnar,radiocarpal,intercarpal-carpometacarpal,second-fifth metacarpophalangeal joints, total score(TS)0-21, higher score(HS)=severe synovitis. O-score:0(no volume increment)-3(100% volume increment) in 23 hand/wrist joints, TS 0-69, HS=more edema. E-score:0(no volume occupied by erosion)-10(100% volume occupied by erosion) in 23 hand/wrist joints, TS 0-230, HS=more erosion.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>S-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.19" spread="3.13"/>
                    <measurement group_id="O2" value="4.90" spread="3.26"/>
                    <measurement group_id="O3" value="4.37" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" spread="1.34"/>
                    <measurement group_id="O2" value="3.14" spread="3.95"/>
                    <measurement group_id="O3" value="3.63" spread="3.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.53" spread="18.47"/>
                    <measurement group_id="O2" value="25.10" spread="28.23"/>
                    <measurement group_id="O3" value="12.60" spread="10.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Magnetic Resonance Imaging (MRI) Findings (S-Score) at Week 12</title>
        <description>MRI of hand/wrist of dominant hand was scored for signs of synovitis (S-score), bone edema (O-score), and bone erosions (E-score) as per OMERACT. S-score: 0 (normal) to 3 (severe) for each of distal radioulnar, radiocarpal, intercarpal-carpometacarpal, second to fifth metacarpophalangeal joints; total score 0 to 21, higher score=severe synovitis.</description>
        <time_frame>Randomization (Week 0), Week 12</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Magnetic Resonance Imaging (MRI) Findings (S-Score) at Week 12</title>
          <description>MRI of hand/wrist of dominant hand was scored for signs of synovitis (S-score), bone edema (O-score), and bone erosions (E-score) as per OMERACT. S-score: 0 (normal) to 3 (severe) for each of distal radioulnar, radiocarpal, intercarpal-carpometacarpal, second to fifth metacarpophalangeal joints; total score 0 to 21, higher score=severe synovitis.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.56"/>
                    <measurement group_id="O2" value="1.36" spread="0.68"/>
                    <measurement group_id="O3" value="-0.29" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Randomization in Magnetic Resonance Imaging (MRI) Findings (O-Score, E-Score) at Week 12</title>
        <description>MRI of hand/wrist of dominant hand was scored for signs of synovitis (S-score), bone edema (O-score), and bone erosions (E-score) as per OMERACT. O-score: 0 (no volume increment) to 3 (100% volume increment) in 23 hand/wrist joints; total score 0 to 69, higher scores=more edema. E-score: 0 (no volume occupied by erosion) to 10 (100% volume occupied by erosion) in 23 hand/wrist joints; total score 0 to 230, higher scores=more erosion.</description>
        <time_frame>Randomization (Week 0), Week 12</time_frame>
        <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Randomization in Magnetic Resonance Imaging (MRI) Findings (O-Score, E-Score) at Week 12</title>
          <description>MRI of hand/wrist of dominant hand was scored for signs of synovitis (S-score), bone edema (O-score), and bone erosions (E-score) as per OMERACT. O-score: 0 (no volume increment) to 3 (100% volume increment) in 23 hand/wrist joints; total score 0 to 69, higher scores=more edema. E-score: 0 (no volume occupied by erosion) to 10 (100% volume occupied by erosion) in 23 hand/wrist joints; total score 0 to 230, higher scores=more erosion.</description>
          <population>m-ITT analysis set. Here, N (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 12: O-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-2.0" upper_limit="0.0"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.5" upper_limit="2.0"/>
                    <measurement group_id="O3" value="-3.00" lower_limit="-4.0" upper_limit="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 12: E-Score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-1.0" upper_limit="0.5"/>
                    <measurement group_id="O2" value="0.00" lower_limit="-0.5" upper_limit="4.0"/>
                    <measurement group_id="O3" value="0.00" lower_limit="0.0" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Treatment Failure for Each Potentially Predictor Variable at Randomization</title>
        <description>Percentage of participants who were treatment failure over 48 weeks as per potentially predictor variables (at randomization) are reported: number of swollen joints/tender joints, DAS28, PGA, PtGA, participant general health VAS, participant pain VAS, clinical disease activity index (CDAI), simplified disease activity index (SDAI), ESR (mm/hour), plasma CRP (mg/L), sensitive serum CRP (mg/L), anti- cyclic citrullinated peptide (anti CCP, units/mL), cartilage oligomeric matrix protein (COMP, units/liter), S-score, O-score, E-score, Joint space narrowing score, erosion score, and mTSS.</description>
        <time_frame>Randomization (Week 0) up to Week 48</time_frame>
        <population>m-ITT analysis set.</population>
        <group_list>
          <group group_id="O1">
            <title>Etanercept 50 mg – Period 2</title>
            <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O2">
            <title>Etanercept 25 mg – Period 2</title>
            <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
          <group group_id="O3">
            <title>Placebo – Period 2</title>
            <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Treatment Failure for Each Potentially Predictor Variable at Randomization</title>
          <description>Percentage of participants who were treatment failure over 48 weeks as per potentially predictor variables (at randomization) are reported: number of swollen joints/tender joints, DAS28, PGA, PtGA, participant general health VAS, participant pain VAS, clinical disease activity index (CDAI), simplified disease activity index (SDAI), ESR (mm/hour), plasma CRP (mg/L), sensitive serum CRP (mg/L), anti- cyclic citrullinated peptide (anti CCP, units/mL), cartilage oligomeric matrix protein (COMP, units/liter), S-score, O-score, E-score, Joint space narrowing score, erosion score, and mTSS.</description>
          <population>m-ITT analysis set.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of swollen joints = 0 (n= 18, 21, 19)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="84.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of swollen joints &gt;0 (n= 5, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of tender joints = 0 (n= 20, 19, 15)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0"/>
                    <measurement group_id="O2" value="47.4"/>
                    <measurement group_id="O3" value="86.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of tender joints &gt;0 to 1 (n= 2, 4, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of tender joints &gt; 1 (n= 0, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &lt;=2.6 (n= 20, 21, 18)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="47.6"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt;2.6 to 3.2 (n= 2, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAS28 &gt;3.2 to 5.1 (n= 0, 1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA = 0 (n= 6, 4, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA &gt;0 to 3 (n= 5, 10, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA &gt;3 to 7 (n= 9, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PGA &gt;7 (n= 3, 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PtGA &lt;= 2.5 (n= 6, 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PtGA &gt;2.5 to 11 (n= 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PtGA &gt;11 to 21 (n= 4, 7, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PtGA &gt;21 (n= 6, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant general health VAS &lt;=3 (n= 6, 7, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant general health VAS &gt;3 to 14 (n= 9,8,4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant general health VAS&gt;14 to 26.5(n=2,7,7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="57.1"/>
                    <measurement group_id="O3" value="71.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant general health VAS &gt;26.5 (n= 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant pain VAS &lt;=3 (n= 7, 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant pain VAS &gt;3 to 10 (n= 6, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant pain VAS &gt;10 to 22 (n=3, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participant pain VAS &gt;22 (n= 7, 7, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI &lt;= 2.8 (n= 14, 13, 13)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="46.2"/>
                    <measurement group_id="O3" value="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDAI &gt;2.8 to 10 (n= 9, 14, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="64.3"/>
                    <measurement group_id="O3" value="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI&lt;= 3.3 (n= 8, 7, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI&gt;3.3 to 11 (n= 13, 15, 12)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI&gt;11 to 26 (n= 2, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SDAI&gt;26 (n= 0, 1, 0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR&lt;= 5 (n= 6, 8, 10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="12.5"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR &gt;5 to 10 (n= 7, 9, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR &gt;10 to 12.5 (n= 0, 3, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ESR &gt;12.5 (n= 6, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma CRP &lt;= 1 (n= 8, 8, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma CRP &gt;1 to 2 (n= 5, 2, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma CRP &gt;2 to 5 (n= 6, 11, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="54.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plasma CRP &gt;5 (n= 4, 6, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="83.3"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitive serum CRP &lt;= 0.6 (n= 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitive serum CRP &gt;0.6 to 1.2 (n= 5, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitive serum CRP &gt;1.2 to 3.3 (n= 6, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sensitive serum CRP &gt;3.3 (n= 4, 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &lt;= 31.7 (n= 5, 8, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;31.7 to 346.8 (n= 8, 3, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;346.8 to 710.8 (n= 5, 4, 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-CCP &gt;710.8 (n= 4, 10, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COMP &lt;= 7.6 (n= 7, 5, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.6"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COMP &gt;7.6 to 9.6 (n= 5, 4, 8)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COMP &gt;9.6 to 12.3 (n= 5, 11, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="63.6"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>COMP &gt;12.3 (n= 5, 5, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="80.0"/>
                    <measurement group_id="O3" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-score &lt;= 1.5 (n= 5, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="40.0"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-score &gt;1.5 to 3.8 (n= 5, 2, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-score &gt;3.8 to 7.5 (n= 5, 8, 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="37.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>S-score &gt;7.5 (n= 3, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.7"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O-score &lt;= 0.5 (n= 6, 7, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O-score &gt;0.5 to 1.5 (n= 4, 6, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O-score &gt;1.5 to 3.5 (n= 7, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>O-score &gt;3.5 (n= 1, 6, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-score &lt;= 3.0 (n= 7, 5, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="20.0"/>
                    <measurement group_id="O3" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-score &gt;3.0 to 9.8 (n= 4, 4, 2)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0"/>
                    <measurement group_id="O2" value="25.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-score &gt;9.8 to 23.0 (n= 5, 4, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="80.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>E-score &gt;23.0 (n= 2, 8, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="62.5"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint space narrowing score &lt;= 0.5 (n= 5, 7, 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint space narrowing score &gt;0.5 to 9.0 (n=5,0,6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint space narrowing score &gt;9.0 to 23.5 (n=7,4,3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint space narrowing score &gt;23.5 (n= 2, 9, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion score &lt;= 9.0 (n= 7, 0, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="66.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion score &gt;9.0 to 21.3 (n= 4, 3, 7)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="85.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion score &gt;21.3 to 47.5 (n= 5, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="50.0"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erosion score &gt;47.5 (n= 3, 8, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mTSS &lt;= 10.0 (n= 5, 6, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mTSS &gt;10.0 to 31.5 (n= 5, 3, 6)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mTSS &gt;31.5 to 70.0 (n= 7, 4, 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="75.0"/>
                    <measurement group_id="O3" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>mTSS &gt;70.0 (n= 2, 9, 3)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Etanercept 50 mg – Period 1</title>
          <description>Etanercept 50 milligram (mg) subcutaneous (SC) injection once weekly along with methotrexate (MTX) 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or intramuscular (IM) injection, depending on the dose a participant was receiving at time of screening, for 8 weeks. Participants who maintained disease activity score based on 28-joints count (DAS28) less than or equal to (&lt;=) 3.2 in Period 1 were randomized in Period 2.</description>
        </group>
        <group group_id="E2">
          <title>Etanercept 50 mg – Period 2</title>
          <description>Etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 more than [&gt;] 5.1, or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 more than or equal to [&gt;=] 1.2, or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits, or disease progression as determined by investigator) were reassigned to Period 3.</description>
        </group>
        <group group_id="E3">
          <title>Etanercept 25 mg – Period 2</title>
          <description>Etanercept 25 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
        </group>
        <group group_id="E4">
          <title>Placebo – Period 2</title>
          <description>Placebo matched to etanercept SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to treatment failure or Week 48/early termination. Participants who showed treatment failure (DAS28 &gt;5.1 or DAS28 &gt;3.2 but &lt;=5.1 along with an increase from baseline in DAS28 &gt;=1.2 or DAS28 &gt;3.2 along with an increase from baseline &gt;=0.6 but &lt;1.2 on 2 consecutive visits or disease progression as determined by investigator) were reassigned to Period 3.</description>
        </group>
        <group group_id="E5">
          <title>Etanercept 50 mg – Period 3</title>
          <description>Participants, who showed treatment failure in Period 2, received etanercept 50 mg SC injection once weekly along with MTX 7.5 mg/week to 25 mg/week as a single dose or divided doses, as oral tablet or as SC or IM injection up to Week 48/early termination.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Endometritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Photokeratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Erythema migrans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Vitamin d deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Lichen planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Dental operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Toe operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="91"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="43"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

